Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
A recent study published in the journal Medicine has found a possible connection between low vitamin D levels and increased ...
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
Wrist-worn devices can predict imminent inflammatory and symptomatic inflammatory bowel disease flare-ups as far in advance ...
Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...
Exposure to various air pollutants, such as PM2.5 and nitrogen oxides, increases the risk for several autoimmune diseases, including psoriasis, lupus and rheumatoid arthritis, according to data ...
The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.
Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback